All In Biotech

Drug Trial Radar · NCT06947304

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

9

Actual

Start

Aug 22, 2025

Primary completion

Aug 13, 2026

Study completion Sep 15, 2026

Sponsor

Lead sponsor
Corcept TherapeuticsIndustry
Sponsor type
Industry
Collaborators
University of Missouri-Columbia
First posted
Apr 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Conditions

  • Nonalcoholic Steatohepatitis (NASH)
  • Metabolic Dysfunction-Associated Steatohepatitis (MASH)
  • Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • Non-alcoholic Fatty Liver Disease (NAFLD)

Interventions

  • MiricorilantDrug

    100 mg administered orally, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in fasting hepatic lipogenesis after 6 weeks of treatmentTime frame: Baseline to Week 6
  2. Change in peak lipogenesis after 6 weeks of treatment.Time frame: Baseline to Week 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Missouri

    Columbia, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.